Komal Jhaveri, MD, Memorial Sloan Kettering Cancer Center and lead author of the EMBER-3 trial, as she discusses the significance of this approval, its impact on the treatment…
Sung-Bae Kim, MD, PhD, Asan Medical Center, Seoul, South Korea, reports on results from the East Asian subgroup of the Phase 3 EMBER‑3 trial, showing that in patients…
Jorge Cortes, MD, director of the Georgia Cancer Center in Augusta, GA, provides a comprehensive look at the current challenges specialists face in providing optimal treatment for patients…
Rahul Seth, DO, assistant professor of medicine at Upstate University Hospital, provides recommendations for the treatment of melanoma. For patients with unresectable melanoma, Dr. Seth recommends a combination…
Eric Jonasch, MD, professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses side effects associated with the novel…
A recent study published in Cell Communication and Signaling presents evidence that cancer treatments that utilize adenoviruses for targeted treatment delivery may trigger additional glioma stem cell formation…
The National Cancer Institute has developed a cloud-based infrastructure, the Cancer Research Data Commons, which allows cancer researchers to access, share, and analyze data from a centralized location,…
David A. Braun, MD, PhD, physician at Dana-Farber Cancer Institute and instructor of medicine at Harvard Medical School, explains that while PD-1 blockade and immune therapies have been…
Isabella C. Glitza Oliva, MD, PhD, MS, assistant professor in the Department of Melanoma Medical Oncology, Division of Cancer Medicine at The University of Texas MD Anderson Cancer…
Joshua K. Sabari, MD, assistant professor, Department of Medicine, NYU Langone Health’s Perlmutter Cancer Center, discusses the limited treatment options for non-small cell lung cancer (NSCLC) patients without…
Gal Markel, MD, PhD, chief scientist and senior oncologist at Sheba Medical Center, discusses the use of fecal microbiota transplant (FMT) for melanoma patients nonresponsive to PD-1 inhibition.…
Chung-Han Lee, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, reports recent findings from a study using pembrolizumab and lenvatinib as a second-line treatment for clear cell…
